Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection

International Journal of Antimicrobial Agents

Volumn 32, Issue 5, 2008, Pages 401-404

  Yanagihara, Katsunori ^a   Ohnishi, Yuriko ^b   Morinaga, Yoshitomo ^a   Nakamura, Shigeki ^a   Kurihara, Shintaro ^a   Seki, Masafumi ^a   Izumikawa, Koichi ^a   Kakeya, Hiroshi ^a   Yamamoto, Yoshihiro ^a   Yamada, Yasuaki ^a   Kohno, Shigeru ^a   Kamihira, Shimeru ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

ME1036; MRSA; Pulmonary infection; Staphylococcus aureus; Vancomycin intermediate

Indexed keywords

AGAR; CARBAPENEM; CYCLOPHOSPHAMIDE; ME 1036; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; IMMUNE DEFICIENCY; LUNG INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD-BORNE PATHOGENS; CARBAPENEMS; LUNG; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS; TISSUE DISTRIBUTION; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 53249122887     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.04.030     Document Type: Article

References (9)

1. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 41 (1997) 135-136
2. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B., et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 340 7 (1999) 493-501
3. Kurazono M., Ida T., Yamada K., Hirai Y., Maruyama T., Shitara E., et al. In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob Agents Chemother 48 8 (2004) 2831-2837
4. Nagura J., Kijima K., Kurazono M., Takahata S., Sugano T., Tanaka Y., et al. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49 8 (2005) 3526-3528
5. Kaneko Y., Yanagihara K., Miyazaki Y., Tsukamoto K., Hirakata Y., Tomono K., et al. Efficacy of DQ-113 against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection. Antimicrob. Agents Chemother 47 12 (2003) 3694-3698
6. Sawai T., Tomono K., Yanagihara K., Yamamoto Y., Kaku M., Hirakata Y., et al. Role of coagulase in a murine model of hematogenous pulmonary infection by intravenous injection of Staphylococcus aureus enmeshed in agar beads. Infect. Immun. 65 2 (1997) 466-471
7. Yanagihara K., Kaneko Y., Sawai T., Miyazaki Y., Tsukamoto K., Hirakata Y., et al. Efficacy of linezolid against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection Antimicrob. Agents Chemother 46 10 (2002) 3288-3291
8. Yanagihara K., Okada M., Fukuda Y., Imamura Y., Kaneko Y., Ohno H., et al. Efficacy of quinupristin/dalfopristin against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection Chemotherapy 50 (2004) 260-264
9. Rybak M.J., Hershberger E., Moldovan T., and Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 44 (2000) 1062-1066